Genmab — Juli 2018
-
i et senere studie (hvor len-dex var kontrolarm) performer len-dex noget bedre - http://www.bloodjournal.org/content/126/23/25?sso-checked=true
-
pfs er her 31 måneder mens kurven er lidt flad omkring de 50%
-
absolut - mine spørgsmål er også bare for at forberede mig på de data vi ser i read-out.
-
Og så kan det vel berolig forum, at pollux vil have pfs på over 40 måneder, mens pfs i første linies kontrolarm forventeligt vil ligge omkring de 30 måneder
-
Ongoing Trials Offer Potential for Second-Generation Therapies as Standard-of-Care in Myeloma https://www.journalofclinicalpathways.com/news/ongoing-trials-offer-potential-second-generation-therapies-standard-care-myeloma
-
repeating this as it also had some MAIA discussion / Extrapolating from Clinical Trials: Daratumumab in MM / https://www.onclive.com/peer-exchange/myeloma-next-gen-regimens/extrapolating-from-clinical-trials-daratumumab-in-mm
-
Er det ikke lidt risky at købe nu hvor først 1120 og derefter 1100 er brudt nedad?
-
De kan sagtens fortsætte nogle dage
endnu med at presse den nedad -
the spanish SELIBORDARA trial started recruiting fast https://clinicaltrials.gov/ct2/history/NCT03589222?A=1&B=2&C=merged
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind